

(19)

Europäisches Patentamt

European Patent Office

Office européen des brevets



(11)

EP 0 463 151 B1

(12)

EUROPEAN PATENT SPECIFICATION

(45) Date of publication and mention
of the grant of the patent:
12.06.1996 Bulletin 1996/24

(51) Int Cl.⁶: C12N 15/00, C12P 21/08,
C12N 5/10, C12N 5/20,
C12N 15/13, A01K 67/027

(21) Application number: 91903098.1

(86) International application number:
PCT/US91/00245

(22) Date of filing: 11.01.1991

(87) International publication number:
WO 91/10741 (25.07.1991 Gazette 1991/17)

(54) GENERATION OF XENOGENEIC ANTIBODIES

ERZUGUNG XENOGENER ANTIKÖRPER

GENERATION D'ANTICORPS XENOGENIQUES

(84) Designated Contracting States:
AT BE CH DE DK ES FR GB GR IT LI LU NL SE

(56) References cited:
EP-A- 0 322 240 WO-A-90/04036
WO-A-92/03918 US-A- 4 950 599
US-A- 4 959 313

(30) Priority: 12.01.1990 US 466008
08.11.1990 US 610515

(43) Date of publication of application:
02.01.1992 Bulletin 1992/01

(60) Divisional application: 95115451.7

(73) Proprietor: CELL GENESYS, INC.
Foster City, CA 94404 (US)

(72) Inventors:
• KUCHERLAPATI, Raju
Darlen, CT 06820 (US)
• JAKOBOVITS, Aya
Menlo Park, CA 94025 (US)

(74) Representative:
Kindler, Matthias, Dr. Dipl.-Chem. et al
Hoffmann, Eitle & Partner
Postfach 81 04 20
81904 München (DE)

- PROCEEDINGS OF THE NATL. ACADEMY OF SCIENCES USA, vol. 86, September 1989, Washington, DC (US); M. BRÜGGEMANN et al., pp. 6709-6713
- TRENDS IN GENETICS, vol. 3, no. 8, August 1987, Cambridge (GB); G. BUTTIN, pp. 205-206
- SCIENCE, vol. 241, 23 September 1988, Lancaster, PA (US); G.D. YANCOPOULOS et al., pp. 1581-1583
- PROCEEDINGS OF THE NATL. ACADEMY OF SCIENCES USA, vol. 83, April 1986, Washington, DC (US); K.-I. YAMAMURA, et al., pp. 2152-2156
- PROCEEDINGS OF THE NATL. ACADEMY OF SCIENCES USA, vol. 86, November 1989, Washington, DC (US); B. KOLLER, et al., pp. 8932-8936
- PROCEEDINGS OF THE NATL. ACADEMY OF SCIENCES USA, vol. 83, July 1986, Washington, DC (US); A. AYARES, et al., pp. 5199-5203
- PROCEEDINGS OF THE NATL. ACADEMY OF SCIENCES USA, vol. 85, February 1988, Washington, DC (US); R. BRINSTER, et al., pp. 836-840
- PROG. NUCLEIC ACID RESEARCH BIOL., vol. 36, 1989; R. KUCHERLAPALATI, pp. 301-310
- PROCEEDINGS OF THE NATL. ACADEMY OF SCIENCES USA, vol. 86, October 1989, Washington, DC (US); A. SHIMIZU, et al., pp. 8020-8023

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

EP 0 463 151 B1

EP 0 463 151 B1

Description

Technical Field

5 The field of this invention is the production of xenogeneic specific binding proteins in a viable non-primate mammalian host.

Background

10 Monoclonal antibodies find use in both diagnosis and therapy. Because of their ability to bind to a specific epitope, they can be uniquely used to identify molecules carrying that epitope or may be directed, by themselves or in conjunction with another moiety, to a specific site for diagnosis or therapy.

Monoclonal antibodies comprise heavy and light chains which join together to define a binding region for the epitope. Each of the chains is comprised of a variable region and a constant region. The constant region amino acid
15 sequence is specific for a particular isotype of the antibody, as well as the host which produces the antibody.

Because of the relationship between the sequence of the constant region and the species from which the antibody is produced, the introduction of a xenogeneic antibody into the vascular system of the host can produce an immune response. Where the xenogeneic antibody may be introduced repetitively, in the case of chronic diseases, it becomes impractical to administer the antibody, since it will be rapidly destroyed and may have an adverse effect. There have
20 been, therefore, many efforts to provide a source of syngeneic or allogeneic antibodies. One technique has involved the use of recombinant DNA technology where the genes for the heavy and light chains from the host were identified and the regions encoding the constant region isolated. These regions were then joined to the variable region encoding portion of other immunoglobulin genes from another species directed to a specific epitope.

While the resulting chimeric partly xenogeneic antibody is substantially more useful than using a fully xenogeneic
25 antibody, it still has a number of disadvantages. The identification, isolation and joining of the variable and constant regions requires substantial work. In addition, the joining of a constant region from one species to a variable region from another species may change the specificity and affinity of the variable regions, so as to lose the desired properties of the variable region. Also, there are framework and hypervariable sequences specific for a species in the variable region. These framework and hypervariable sequences may result in undesirable antigenic responses.

30 It would therefore be more desirable to produce allogeneic antibodies for administration to a host by immunizing the host with an immunogen of interest. For primates, particularly humans, this approach is not practical. The human antibodies which have been produced have been based on the adventitious presence of an available spleen, from a host which had been previously immunized to the epitope of interest. While human peripheral blood lymphocytes may be employed for the production of monoclonal antibodies, these have not been particularly successful in fusions and
35 have usually led only to IgM. Moreover, it is particularly difficult to generate a human antibody response against a human protein, a desired target in many therapeutic and diagnostic applications. There is, therefore, substantial interest in finding alternative routes to the production of allogeneic antibodies for humans.

Relevant Literature

40 Thomas and Capocchi, *Cell*, **51**, 503-512, 1987. Koller and Smithies, *Proc. Natl. Acad. Sci. USA*, **86**, 8932-8935, 1989, describe inactivating the B2microglobulin locus by homologous recombination in embryonic stem cells. Berman et al., *EMBO J.*, **7**, 727-738, 1988, describe the human Ig VH locus. Burke, et al., *Science*, **236**, 806-812, 1987, describe yeast artificial chromosome vectors. See also, Garza et al., *Science*, **246**, 641-646, 1989, and Brownstein et al., *Science*, **244**, 1348-1351, 1989. Sakano, et al., describe a diversity segment of the immunoglobulin heavy chain genes. Sakano et al., *Nature*, **290**, 562-565, 1981. Tucker et al., *Proc. Natl. Acad. Sci. USA*, **78**, 7684-7688, 1981, describe the mouse IgA heavy chain gene sequence. Blankenstein and Kruwinkkel *Eur. J. Immunol.*, **17**, 1351-1357, 1987, describe the mouse variable heavy chain region. See also, Joyner et al., *Nature*, **338**, 153-155, 1989. Traver et al., *Proc. Nat. Acad. Sci. USA*, **86**, 5898-5902, 1989, and Panchis et al., *Proc. Nat. Acad. Sci. USA*, **87**, 5109-5113, 1990. Brügge-
50 mann et al, *Proc. Natl. Acad. Sci. USA*, **86**, 6709-6713, 1989, describes the introduction of a heavy chain minilocus in fertilized mouse eggs.

SUMMARY OF THE INVENTION

55 Xenogeneic specific binding proteins are produced in a non-primate viable mammalian host by immunization of the non-primate mammalian host with an appropriate immunogen.

The host is characterized by: (1) being incapable of producing endogenous immunoglobulin due to a lesion in the J region of at least one copy of the immunoglobulin heavy chain locus; and, preferably, (2) an exogenous immunoglob-

EP 0 463 151 B1

ulin locus comprising at least one immunoglobulin constant region, or protein thereof, immunoglobulin sequences providing for the components of the variable region of at least one of the light and heavy chains, and at least one intron with appropriate splicing sites for excision and assembly of a functional immunoglobulin subunit. Thus, the non-primate mammalian host will comprise at least one xenogeneic constant region or protein thereof capable of being spliced to a functional J region of an endogenous or exogenous immunoglobulin locus, may have an entire immunoglobulin locus of the host substituted by a portion or an entire xenogeneic immunoglobulin locus, or may have a xenogeneic immunoglobulin locus inserted into a chromosome of the host cell and an inactivated endogenous immunoglobulin region. These various alternatives will be achieved, at least in part, by employing homologous recombination at the immunoglobulin loci for the heavy and light chains.

DESCRIPTION OF SPECIFIC EMBODIMENTS

Novel transgenic mammalian hosts, other than primates, particularly other than human, are provided, where the host is capable of mounting an immune response to an immunogen, where the response produces antibodies having primate, particularly human, constant and/or variable regions or such other effector peptide sequences of interest. The hosts are characterized by being capable of producing xenogeneic or modified antibodies as a result of substitution and/or inactivation of the endogenous immunoglobulin subunit encoding loci. The modifications retain at least a portion of the constant regions which provide for assembly of the variable region binding site bonded at the C-terminus to a functional peptide. The functional peptide may take many forms or conformations and may serve as an enzyme, growth factor, binding protein, ligand, cytokine, effector protein, chelating proteins, etc. The antibodies may be any isotype, e.g., IgA, D, E, G or M or subtypes within the isotype.

A number of strategies may be employed to achieve the desired transgenic hosts. Various transgenic hosts may be employed, particularly murine, lagomorpha, ovine, porcine, equine, canine, feline, or the like, normally other than primate. For the most part, mice have been used for the production of B-lymphocytes for immortalization for the production of antibodies. Since mice are easy to handle, can be produced in large quantities, and are known to have an extensive immune repertoire, mice will usually be the animal of choice. Therefore, in the following discussion, the discussion will refer to mice, but it should be understood that other animals, particularly non-primate mammals, may be readily substituted for the mice, following the same procedures.

In one strategy, as individual steps, the human heavy and light chain immunoglobulin gene complexes are introduced into the mouse germ line and in a separate step the corresponding mouse genes are rendered non-functional. Human heavy and light chain genes are reconstructed in an appropriate eukaryotic or prokaryotic microorganism and the resulting DNA fragments can be introduced into pronuclei of fertilized mouse oocytes or embryonic stem cells. Inactivation of the endogenous mouse immunoglobulin loci is achieved by targeted disruption of the appropriate loci by homologous recombination in mouse embryonic stem cells. In each case chimeric animals are generated which are derived in part from the modified embryonic stem cells and are capable of transmitting the genetic modifications through the germ line. The mating of mouse strains with human immunoglobulin loci to strains with inactivated mouse loci will yield animals whose antibody production is purely human.

These strategies are based on the known organization of the immunoglobulin chain loci in a number of animals, since the organization, relative location of exons encoding individual domains, and location of splice sites and transcriptional elements, is understood to varying degrees. In the human, the immunoglobulin heavy chain locus is located on chromosome 14. In the 5' - 3' direction of transcription, the locus comprises a large cluster of variable region genes (V_H), the diversity (D) region genes, followed by the joining (J_H) region genes and the constant (C_H) gene cluster. The size of the locus is estimated to be about 2,500 kilobases (kb). During B-cell development, discontinuous gene segments from the germ line IgH locus are juxtaposed by means of a physical rearrangement of the DNA. In order for a functional heavy chain Ig polypeptide to be produced, three discontinuous DNA segments, from the V_H , D, and J_H regions must be joined in a specific sequential fashion; V_H to DJ_H , generating the functional unit V_HDJ_H . Once a V_HDJ_H has been formed, specific heavy chains are produced following transcription of the Ig locus, utilizing as a template the specific $V_HDJ_HC_H$ unit comprising exons and introns. There are two loci for Ig light chains, the κ locus on human chromosome 2 and the λ locus on human chromosome 22. The structure of the IgL loci is similar to that of the IgH locus, except that the D region is not present. Following IgH rearrangement, rearrangement of a light chain locus is similarly accomplished by V_L and J_L joining of the κ or λ chain. The sizes of the λ and κ loci are each approximately 1000 kb. Expression of rearranged IgH and an Ig κ or Ig λ light chain in a particular B-cell allows for the generation of antibody molecules.

In order to isolate, clone and transfer the IgH_{hu} locus, a yeast artificial chromosome may be employed. The entire IgH_{hu} locus can be contained within one or a few yeast artificial chromosome (YAC) clones. The same is true for the Ig light chain loci. Subsequent introduction of the appropriate heavy chain or light chain YAC clones into recipient yeast allows for the reconstitution of intact germ line Ig loci by homologous recombination between overlapping regions of homology. In this manner, the isolation of DNA fragments encoding the human Ig chain is obtained.

EP 0 463 151 B1

In order to obtain a broad spectrum of high affinity antibodies, it is not necessary that one include the entire V region. Various V region gene families are interspersed within the V region cluster. Thus, by obtaining a subset of the known V region genes of the human heavy and light chain Ig loci (Berman *et al.*, EMBO J. (1988) 7: 727-738) rather than the entire complement of V regions, the transgenic host may be immunized and be capable of mounting a strong immune response and provide high affinity antibodies. In this manner, relatively small DNA fragments of the chromosome may be employed, for example, a reported 670 kb fragment of the IgH locus is shown in Figure 1b of said document. This NotI-NotI restriction fragment would serve to provide a variety of V regions, which will provide increased diversity by recombining with the various D and J regions and undergoing somatic mutation.

In order to provide for the production of human antibodies in a xenogeneic host, it is necessary that the host be competent to provide the necessary enzymes and other factors involved with the production of antibodies, while lacking competent endogenous genes for the expression of heavy and light subunits of immunoglobulins. Thus, those enzymes and other factors associated with germ line rearrangement, splicing, somatic mutation, and the like, will be functional in the xenogeneic host. What will be lacking is a functional natural region comprising the various exons associated with the production of endogenous immunoglobulin subunits.

The human DNA may be introduced into the pronuclei of fertilized oocytes or embryonic stem cells. The integration may be random or homologous depending on the particular strategy to be employed. Thus, by using transformation, using repetitive steps or in combination with breeding, transgenic animals may be obtained which are able to produce human antibodies in the substantial absence of light or heavy host immunoglobulin subunits.

To inactivate the host immunoglobulin loci, homologous recombination may be employed, where DNA is introduced at the immunoglobulin heavy chain and light chain loci which inhibits the production of endogenous immunoglobulin subunits. Since there are two heavy chain alleles and two light chain loci, each with two alleles, although one may choose to ignore the λ loci, there will have to be multiple transformations which result in inactivation of each of the alleles. (By transformation is intended any technique for introducing DNA into a viable cell, such as conjugation, transformation, transfection, transduction, electroporation, lipofection, biolistics, or the like.) Homologous recombination may be employed to functionally inactivate each of the loci, by introduction of the homologous DNA into embryonic stem cells, followed by introduction of the modified cells into recipient blastocysts. Subsequent breeding allows for germ line transmission of the inactivated locus. One can therefore choose to breed heterozygous offspring and select for homozygous offspring from the heterozygous parents or again one may use the embryonic stem cell for homologous recombination and inactivation of the comparable locus.

While the number of transformation steps may be reduced by providing at least a fragment of the human immunoglobulin subunit locus for homologous recombination with the analogous endogenous immunoglobulin, in the event only transformation is used and the human locus is integrated into the host genome in random fashion, a total of eight transformations may be required.

For inactivation, a lesion in the target locus resulting in the prevention of expression of an immunoglobulin subunit of that locus is employed. Thus, the important factor is that Ig germ line gene rearrangement is inhibited, or a functional message encoding the immunoglobulin subunit cannot be produced, either due to failure of transcription, failure of processing of the message, or the like.

For inactivating the immunoglobulin heavy chain subunit locus, the lesion will be introduced into the J region of the heavy chain immunoglobulin subunit locus. Thus, one produces a construct which lacks a functional J region and may comprise the sequences of the J region adjacent to and upstream and/or downstream from the J region or comprises all or part of the region with an inactivating insertion in the J region. The insertion may be 50 bp or more, where such insertion results in disruption of formation of a functional mRNA. Desirably, the J region in whole or substantial part, usually at least about 75% of the locus, preferably at least about 90% of the locus, is deleted. If desired, the lesion between the two flanking sequences defining the homologous region may extend beyond the J region, into the variable region and/or into the constant region. In the light chain, J, V or C regions, or enhancer regions may be used.

Desirably, a marker gene is used to replace the J region. Various markers may be employed, particularly those which allow for positive selection. Of particular interest is the use of G418 resistance, resulting from expression of the gene for neomycin phosphotransferase.

Upstream and/or downstream from the target gene construct may be a gene which provides for identification of whether a double crossover has occurred. For this purpose, the Herpes simplex virus thymidine kinase gene may be employed, since cells expressing the thymidine kinase gene may be killed by the use of nucleoside analogs such as acyclovir or gancyclovir, by their cytotoxic effects on cells that contain a functional HSV-tk gene. The absence of sensitivity to these nucleoside analogs indicates the absence of the HSV-thymidine kinase gene and, therefore, where homologous recombination has occurred, that a double crossover has also occurred.

While the presence of the marker gene in the genome will indicate that integration has occurred, it will still be necessary to determine whether homologous integration has occurred. This can be achieved in a number of ways. For the most part, DNA analysis will be employed to establish the location of the integration. By employing probes for the insert and then sequencing the 5' and 3' regions flanking the insert for the presence of the target locus extending

EP 0 453 151 B1

beyond the flanking region of the construct or identifying the presence of a deletion, when such deletion has been introduced, the desired integration may be established.

The polymerase chain reaction (PCR) may be used with advantage in detecting the presence of homologous recombination. Probes may be used which are complementary to a sequence within the construct and complementary to a sequence outside the construct and at the target locus. In this way, one can only obtain DNA chains having both the primers present in the complementary chains if homologous recombination has occurred. By demonstrating the presence of the probes for the expected size sequence, the occurrence of homologous recombination is supported.

The construct may further include a replication system which is functional in the non-primate mammalian host cell. For the most part, these replication systems will involve viral replication systems, such as Simian virus 40, Epstein-Barr virus, polyoma virus, papilloma virus, and the like. Various transcriptional initiation systems may be employed, either from viruses or from mammalian genes, such as SV40, metallothionein-I and II genes, p-actin gene, adenovirus early and late genes, phosphoglycerate kinase gene, RNA polymerase II gene, or the like. In addition to promoters, wild-type enhancers may be employed to further enhance the expression of the marker gene.

In constructing the subject constructs for homologous recombination, a replication system for procaryotes, particularly *E. coli*, may be included, for preparing the construct, cloning after each manipulation, analysis, such as restriction mapping or sequencing, expansion and isolation of the desired sequence. Where the construct is large, generally exceeding about 50 kbp, usually exceeding 100 kbp, and usually not more than about 1000kbp, a yeast artificial chromosome (YAC) may be used for cloning of the construct.

Once a construct has been prepared and any undesirable sequences removed, e.g., procaryotic sequences, the construct may now be introduced into the target cell. Any convenient technique for introducing the DNA into the target cells may be employed. Techniques include spheroplast fusion, lipofection, electroporation, calcium phosphate-mediated DNA transfer or direct microinjection. After transformation or transfection of the target cells, target cells may be selected by means of positive and/or negative markers, as previously indicated, neomycin resistance and acyclovir or gancyclovir resistance. Those cells which show the desired phenotype may then be further analyzed by restriction analysis, electrophoresis, Southern analysis, PCR, or the like. By identifying fragments which show the presence of the lesion(s) at the target locus, one can identify cells in which homologous recombination has occurred to inactivate a copy of the target locus.

The above described process may be performed first with a heavy chain locus in an embryonic stem cell and then maturation of the cells to provide a mature fertile host. Then by breeding of the heterozygous hosts, a homozygous host may be obtained or embryonic stem cells may be isolated and transformed to inactivate the second IgH locus, and the process repeated until all the desired loci have been inactivated. Alternatively, the light chain locus may be the first. At any stage, the human loci may be introduced.

As already indicated, the target locus may be substituted with the analogous human locus. In this way, the human locus will be placed substantially in the same region as the analogous host locus, so that any regulation associated with the position of the locus will be substantially the same for the human immunoglobulin locus. For example, by isolating the entire V_H gene locus (including V, D, and J sequences), or portion thereof, and flanking the human locus with sequences from the mouse locus, preferably sequences separated by at least about 5 kbp, in the host locus, preferably at least about 10 kbp in the host locus, one may insert the human fragment into this region in a recombinational event(s), substituting the human immunoglobulin locus for the variable region of the host immunoglobulin locus. In this manner, one may disrupt the ability of the host to produce an endogenous immunoglobulin subunit, while allowing for the promoter of the human immunoglobulin locus to be activated by the host enhancer and regulated by the regulatory system of the host.

Once the human loci have been introduced into the host genome, either by homologous recombination or random integration, and host animals have been produced with the endogenous immunoglobulin loci inactivated by appropriate breeding of the various transgenic or mutated animals, one can produce a host which lacks the native capability to produce endogenous immunoglobulin subunits, but has the capacity to produce human immunoglobulins with at least a significant portion of the human repertoire.

The functional inactivation of the two copies of each of the three host Ig loci, where the host contains the human IgH and the human Ig κ and/or λ loci would allow for the production of purely human antibody molecules without the production of host or host/human chimeric antibodies. Such a host strain, by immunization with specific antigens, would respond by the production of mouse B-cells producing specific human antibodies, which B-cells could be fused with mouse myeloma cells or be immortalized in any other manner for the continuous stable production of human monoclonal antibodies.

The subject methodology and strategies need not be limited to producing complete immunoglobulins, but provides the opportunity to provide for regions joined to a portion of the constant region, e.g., C_{H1} , C_{H2} , C_{H3} , or C_{H4} , or combination thereof. Alternatively, one or more of the exons of the C_H and C_K or C_L regions may be replaced or joined to a sequence encoding a different protein, such as an enzyme, e.g., plasminogen activator, superoxide dismutase, etc.; toxin A chain, e.g., ricin, abrin, diphtheria toxin, etc.; growth factors; cytotoxic agent, e.g., TNF, or the like. See, for

EP 0 463 151 B1

example, WO 89/07142; WO 89/09344; and WO 88/03559. By inserting the protein of interest into a constant region exon and providing for splicing of the variable region to the modified constant region exon, the resulting binding protein may have a different C-terminal region from the immunoglobulin. By providing for a stop sequence with the inserted gene, the protein product will have the inserted protein as the C-terminal region. If desired, the constant region may be entirely substituted by the other protein, by providing for a construct with the appropriate splice sites for joining the variable region to the other protein.

The antibodies or antibody analog producing B-cells from the transgenic host may be used for fusion to a mouse myeloid cell to produce hybridomas or immortalized by other conventional process, e.g., transfection with oncogenes. These immortalized cells may then be grown in continuous culture or introduced into the peritoneum of a compatible host for production of ascites.

The subject invention provides for the production of polyclonal human anti-serum or human monoclonal antibodies or antibody analogs. Where the non-primate mammalian host has been immunized with an immunogen, the resulting human antibodies may be isolated from other proteins by using an affinity column, having an Fc binding moiety, such as protein A, or the like.

For producing animals from embryonic stem cells, after transformation, the cells may be plated onto a feeder layer in an appropriate medium, e.g. fetal bovine serum enhanced DMEM. Cells containing the construct may be detected by employing a selective medium and after sufficient time for colonies to grow, colonies may be picked and analyzed for the occurrence of integration or homologous recombination. As described previously, the PCR may be used, with primers within or without the construct sequence, but at the target locus.

Those colonies which show homologous recombination may then be used for embryo manipulation and blastocyst injection. Blastocysts may be obtained from females by flushing the uterus 3-5 days after ovulation. The embryonic stem cells may then be trypsinized and the modified cells added to a droplet containing the blastocyst. At least one and up to thirty modified embryonic stem cells may be injected into the blastocoel of the blastocyst. After injection, at least one and no more than about fifteen of the blastocysts are returned to each uterine horn of pseudo-pregnant females. Females are then allowed to go to term and the resulting litter screened for mutant cells having the construct.

The mammals may be any non-human, particularly non-primate mammal, such as laboratory animals, particularly small laboratory animals, such as mice, rats, guinea pigs, etc., domestic animals, pets, etc.


The following examples are offered by way of illustration and not by way of limitation.

EXPERIMENTAL

Inactivation of the mouse heavy chain J genes Construction of the inactivation vector

A 6.4 Kb EcoRI fragment, containing the mouse heavy chain J genes and flanking sequences, is cloned from a Balb/c mouse embryo genomic library using the probes described in Sakano *et al.*, *Nature* 290:562-565, 1981. This fragment (mDJ) is inserted into EcoRI-digested pUC19 plasmid (pmDJ). A 2.9 Kb fragment, containing the 4 J genes, is deleted by XhoI-ScaI digestion (pmD&JNeo, see Chart 1). An 1150 bp XhoI-BamHI fragment, containing a neomycin-resistance gene driven by the Herpes simplex virus thymidine kinase gene (HSV-tk) promoter and a polyoma enhancer is isolated from pMCINeo (Thomas and Capecchi, *Cell*, 51, 503-512, 1987). A synthetic adaptor is added onto this fragment to convert the BamHI end into a ScaI end and the resulting fragment is joined to the XhoI-ScaI pmD&J to form the inactivation vector (pmD&J.Neo) in which the 5' to 3' orientation of the neomycin and the heavy chain promoters is identical. This plasmid is linearized by NdeI digestion before transfection to ES cells. The sequences driving the homologous recombination event are 3 kb and 0.5 kb fragments, located 5' and 3' to the neomycin gene, respectively.

EP 0 463 151 B1

Chart 1**Mouse Heavy Chain J Genes Inactivation Vector****(A) Targeted mouse heavy chain J genes****(B) Inactivation vector mDAJ.Neo**

The ES cell line E14TG2a (Hooper *et al.*, *Nature*, 326:292-295, 1987) is cultured on mitomycin-treated primary embryonic fibroblast-feeder layers essentially as described (Doetschman *et al.*, *J. Embryol. Exp. Morphol.* 87:27-45, 1985). The embryonic fibroblasts are prepared from embryos from C57BL/6 females that are mated 14 to 17 days earlier with a male homozygous for a neomycin transgene (Gossler *et al.*, *PNAS* 83:9065-9069, 1986). These cells are capable of growth in media containing G418. Electroporation conditions are described by (Boggs *et al.*, *Ex. Hematol. (NY)* 149:986-994, 1986). ES cells are trypsinized, resuspended in culture media at a concentration of 4×10^7 /ml and electroporated in the presence of the targeting DNA at a concentration of 12nM in the first experiment and 5nM DNA in the second. A voltage of 300 V with a capacitance of 150-250 μ F is found optimal with an electroporation cell of 5 mm length and 100 mm² cross-section. 5×10^6 electroporated cells are plated onto mitomycin-treated fibroblasts in 100 mm dishes in the presence of Dulbecco's modified Eagle's media (DMEM) supplemented with 15% fetal bovine serum (FBS) and 0.1 mM 2-mercaptoethanol. The media is replaced 24 hr after electroporation with media containing 200 μ g/ml G418.

ES colonies resulting 10-14 days after electroporation are picked with drawn out capillary pipettes for analysis using PCR. Half of each picked colony is saved in 24-well plates already seeded with mitomycin-treated feeder cells. The other halves, combined in pools of 3-4, are transferred to Eppendorf tubes containing approximately 0.5 ml of PBS and analyzed for homologous recombination by PCR. Conditions for PCR reactions are essentially as described (Kim and Smithies, *Nucleic Acids Res.* 16:8887-8893, 1988). After pelleting, the ES cells are resuspended in 5 μ l of PBS and are lysed by the addition of 55 μ l of H₂O to each tube. DNases are inactivated by heating each tube at 95°C for 10 min. After treatment with proteinase K at 55°C for 30 min, 30 μ l of each lysate is transferred to a tube containing 20 μ l of a reaction mixture including PCR buffer: 1.5 μ g of each primer, 3U of Taq polymerase, 10% DMSO, and dNTPs, each at 0.2 mM. The PCR expansion employs 55 cycles using a thermocycler with 65 seconds melt at 92°C and a 10 min annealing and extension time at 65°C. The two priming oligonucleotides are TGGCGGACCGCTATCCCCAGGAC and TAGCCTGGGTCCCTCCTTAC, which correspond respectively to a region 650 bases 3' of the start codon of the

EP 0 463 151 B1

neomycin gene and sequences located in the mouse heavy chain gene, 1100 bases 3' of the insertion site. 20 μ l of the reaction mix is electrophoresed on agarose gels and transferred to nylon membranes (Zeta Bind). Filters are probed with a 32 P-labelled fragment of the 991 bp XbaI fragment of the J-C region.

5

10

15

20

25

30

35

40

45

50

55

EP 0 463 151 B1

Inactivation of the mouse Ig heavy chain J genes in ES cells.Construction of the inactivation vector

5 A 6.1-Kb EcoRI fragment, containing the mouse immunoglobulin heavy chain J region genes and flanking sequences, cloned from a Balb/c mouse embryo genomic library and inserted into pUC18 (pJH), was digested with XhoI and NaeI to delete an about 2.3 kbp fragment containing the four J genes (see Chart 2A). An about 1.1 kbp XhoI-BamHI fragment, blunted at the BamHI site, containing a neomycin resistance gene driven by the Herpes simplex virus thymidine kinase gene (HSV-tk) promoter and polyoma enhancer was isolated from pMCiNeo (Thomas and Capecchi, 10 Cell, 51, 503-512, 1987). This fragment was inserted into the XhoI-NaeI deleted pJH to form the inactivation vector (pmH&J, see Chart 2B), in which the transcriptional orientation of the neomycin and the heavy chain genes is the same. This plasmid was linearized by NdeI digestion before transfection to ES cells. The sequences driving the homologous recombination event are about 2.8 kbp and about 1.1 kbp fragments, located 5' and 3' to the neomycin gene, respectively.

15 Culturing, Electroporation, and Selection of ES cells

The ES cell line E14TG2a (Koller and Smithies, 1989, PNAS, USA, 86, 8932-8935) was cultured on mitomycin C-treated embryonic fibroblast feeder layers as described (Koller and Smithies, 1989, PNAS, USA, 86, 8932-8935). ES 20 cells were trypsinized, resuspended in HBS buffer (pH 7.05; 137mM NaCl, 5mM KCl, 2mM CaCl₂, 0.7mM Na₂HPO₄, 21mM HEPES pH7.1) at a concentration of 2x10⁷/ml and electroporated in the presence of 50 µg/ml of the linearized inactivation vector. Electroporation was carried out with a BioRad Gene Pulser using 240 volts and 500µF capacitance. 5x10⁶ electroporated cells were plated onto mitomycin C-treated fibroblasts in 100mm dishes in the presence of Dulbecco's modified Eagle's media (DMEM) supplemented with 15% fetal bovine serum and 0.1 mM 2-mercaptoethanol. 25 The media was replaced 24 hr after electroporation with media containing 200µg/ml G418. G418-resistant ES colonies resulting 12-14 days after electroporation were picked with drawn out capillary pipettes for analysis using the polymerase chain reaction (PCR). Half of each picked colony was transferred to an individual well of a 24-well plate, already seeded with mitomycin C-treated feeder cells. The other halves, combined in pools of four, were transferred to Eppendorf tubes containing 0.3 ml of PBS and cell lysates were prepared for PCR analysis as described by Joyner et al 30 (Nature, 338:153-155, 1989). The PCR reaction included 5-20µl of the cell lysate, 1µm of each primer, 1.5u of Taq polymerase and 200µM of dNTPs. The PCR amplification employed 45 cycles using a thermal cycler (Perkin-Elmer Cetus), with 1 min. melt at 94°C, 2 min. annealing at 55°C, and 3 min. extension at 72°C. The two priming oligonucleotides are ACGGTATCGCCGCTCCCGAT and AGTCACTGTAAAGACTTCGGGTA, which correspond respectively to about 120 bases 5' of the BamHI site of the neomycin gene, and to the sequences located in the mouse heavy chain 35 gene, about 160 bases 3' of the insertion site. Successful homologous recombination gives rise to an about 1.4 kbp fragment. 20µl of the reaction mixture is electrophoresed on 1% agarose gels, stained with ethidium bromide and transferred to nylon membranes (Gene Screen). Filters were probed with a ³²P-labelled EcoRI-PstI about 1.4 kbp fragment located in the mouse heavy chain, 3' of the insertion site (see Chart 2). For further analysis, genomic DNA 40 was prepared from ES cells, digested with restriction enzymes as recommended by the manufacturers, and fragments were separated on 1% agarose gels. DNA was transferred to nylon membranes (Gene Screen) and probed with the ³²P-labelled fragment as described above.

Analysis of G418-resistant ES colonies

45 In the first experiment, PCR analysis of the pooled colonies detected one positive PCR signal of the expected size (about 1.4kbp) out of 34 pools representing 136 G418-resistant colonies. The four individual colonies that had contributed to this positive pool were analyzed individually by PCR, and a positive clone, ES33D5, was identified. Similar analysis of 540 G418-resistant colonies obtained in the second experiment yielded 4 additional positive clones (ES41-1, ES61-1, ES65-1, ES110-1).

50 In order to verify the targeting disruption of one copy of the J genes, (the gene is autosomal and thus present in two copies), the PCR positive clones were expanded and genomic DNA was prepared, digested with HindIII or with SacI and analyzed by Southern analysis as described using the EcoRI-PstI probe.

The replacement of the J genes by insertion of the neomycin gene by an homologous recombination event results in an HindIII fragment, detectable with the EcoRI-PstI probe, which is about 1.9 kbp longer than the equivalent fragment 55 in the native locus, due to the loss of two HindIII sites located in the deleted J gene region (see Chart 2C). Southern analysis of each of the 5 positive clones by HindIII digestion gave a pattern which indicated that one of the two copies of the heavy chain J genes had been disrupted. Three labelled fragments were detected; one fragment (about 760 bp), identical in size to that present in untreated cells at the same intensity, one fragment (about 2.3kbp) identical in

EP 0 463 151 B1

size to that present in untreated cells, but of decreased intensity in the PCR positive clone, and an additional fragment about 4.2 kbp, the size predicted for an homologous recombination event, present only in the PCR-positive clones. Similarly, the replacement of the J genes by the neomycin gene by an homologous recombination event results in a loss of one SacI site and the appearance of a fragment, detectable with the EcoRI-PstI probe, which is about 570 bp smaller than the equivalent fragment in the native locus (see Chart 2C). Southern analysis of the clones by SacI digestion gave the expected pattern of one native and one targeted allele: about 4.0 kbp fragment, identical in size to that detected in untreated cells, but of decreased intensity in the 5 positive clones, and an additional fragment of about 3.4 kbp, the size predicted for a targeted homologous recombination event, present only in the identified clones. Re-hybridization of the Southern blots with a probe for the neomycin gene shows that only the 4.2 kbp and 3.4 kbp fragments, resulting from the HindIII and the SacI digestion, respectively, hybridized to the probe as predicted by the targeting event.


Inactivation of mouse immunoglobulin heavy chain J genes in mice15 Injection of targeted ES cells into mouse blastocysts and generation of chimeric offsprings

Mice were purchased from Jackson Laboratories (Bar Harbor, ME). Three and a half day old C57BL/6 blastocysts were obtained from 4-5 week old superovulated females as described by Koller *et al.* 1989 (supra). ES cells were trypsinized, washed once with fresh DMEM media and diluted to about 1×10^6 /ml in M2 media. About 5 μ l of cells were added to a 150 μ l droplet of M2 media, under paraffin oil, containing the blastocysts. Ten to fifteen cells were injected into the blastocoel of each blastocyst. Six to nine ES cell-containing blastocysts were returned to each uterine horn of C57BL/6 x DBA F1 pseudopregnant females mated 2.5 days previously with vasectomized males. Pups derived from the injected blastocysts were generally born 16-18 days later. The contribution of the ES cells to the offspring was judged visually by examination of the coat color of the pups. The blastocysts were obtained from C57BL/6 mice, which are solid black in color. The ES cell line E14TG2a, the parental line from which the targeted cell lines were derived, was isolated from 129/O1a mice. This mouse strain is cream in color, the combined effect of three color genes, the dominant A^y allele at the agouti locus, the recessive pink-eyed-dilute allele at the p locus and the recessive C^{ch} allele at the C locus. Offspring in which the ES cells participated in the formation of the animal had coats containing brown and cream hair. The ES cell line ES41-1 carrying inactivated mouse immunoglobulin heavy chain, was injected into C57BL/6 mouse blastocysts as described above. Six out of the 18 surviving pups had a high degree of coat color chimerism (70-90%). PCR analysis of DNA isolated from chimeric newborn pups from a female implanted with blastocysts injected with the inactivated ES cells, indicated that the mutated immunoglobulin heavy chain locus is present in a variety of organs such as spleen, thymus, kidney, liver, brain and skin.

35 Inactivation of the mouse Ig kappa chain J genes in ES cells

A 5.6 Kb HindIII-BamHI fragment, containing the mouse immunoglobulin kappa chain J region genes and 3' flanking sequences, cloned from a Balb/c mouse embryo genomic library and inserted into pBluescriptSK vector to yield the plasmid (pKJ). pKJ was digested with HindIII and PstI to delete an about 1.7 Kb fragment containing the 5 J genes (see Chart 3). A 570 bp blunt HindIII fragment, spanning the

EP 0 463 151 B1

Chart 3Kappa chain inactivation vector

region 5' to the HindIII site adjacent to the kappa J region, was cloned from mouse genomic DNA by polymerase chain reaction (PCR). This fragment was inserted into HindIII-SmaI digested pC cloning vector (Marsh *et al.*, 1984, *Gene*, 32:481-485) and was excised by digestion with KpnI-XhoI. An about 1.1 Kb XhoI-BamHI fragment, blunted at the BamHI site, containing the neomycin resistance gene driven by the Herpes simplex virus thymidine kinase gene (HSV-tk) promoter and polyoma enhancer was isolated from pMCiNeo (Thomas and Capecchi, 1987, *supra*). The neomycin fragment was inserted into the HindIII-PstI deleted pKJ, which was blunted at the PstI site, 5' to the kappa sequences. The resulting plasmid was digested with KpnI and XhoI and the 570 bp KpnI-XhoI kappa fragment was inserted into the KpnI-XhoI cleaved vector, 5' to the neomycin gene, to generate the inactivation vector (pmK&J, see chart 3). The transcriptional orientation of the neomycin and the kappa chain genes is the same in pmK&J. The plasmid was linearized by ApaLI before transfection into ES cells. The linearized sequence has about 3.8 Kb and 570 bp of homology to the cellular sequences, located 3' and 5' to the neomycin gene, respectively.

Analysis of G418-resistant ES colonies

Electroporation of the kappa inactivation vector into ES cells and screening for homologous recombination events

EP 0 463 151 B1

was carried out as described for the inactivation of the immunoglobulin heavy chain. G418-resistant ES colonies were analysed for homologous recombination targeting by PCR using two priming oligonucleotides CGGTTGCTGTTGTATC-CATAACTC and CATCAGAGCAGCCGATTGTCTG, which correspond respectively to the sequences located in the mouse kappa chain gene, about 67 bp 5' of the insertion site, and about 370 bp 3' of the XhoI site of the neomycin gene. A ³²P-labelled 80 base oligonucleotide, which starts about 10 bp 5' of the insertion site, was used as a probe to detect the targeted PCR product. Successful homologous recombination gives rise to an about 1030 bp fragment. PCR analysis of 650 G418-resistant colonies detected 3 positive colonies (ES56-1, ES69-4, ES147-1). Southern analysis of these colonies confirmed the integration of the inactivation vector into one allele of the kappa immunoglobulin loci leading to a deletion of the J region.

Production of human Ig in transgenic mice

Example: production of human heavy chain in transgenic mice DNA vector

An SpeI fragment, spanning the human heavy chain VH6-D-J-Cμ-Cδ region (Berman *et al.*, *EMBO J.* (1988) 7: 727-738; see Chart 4) is isolated from a human library cloned into a yeast artificial chromosome (YAC) vector (Burke *et al.*, *Science*, 236: 806-812) using DNA probes described by Berman *et al.* (*EMBO J.* (1988) 7: 727-738). One clone is obtained which is estimated to be about 100 Kb. The isolated YAC clone is characterized by pulsed-field gel electrophoresis (Burke *et al.*, *supra*; Brownstein *et al.*, *Science*, 244: 1348-1351), using radiolabelled probes for the human heavy chain (Berman *et al.*, *supra*).

Introduction of YAC clones into embryos

High molecular weight DNA is prepared in agarose plugs from yeast cells containing the YAC of interest (i.e., a YAC containing the aforementioned SpeI fragment from the IgH locus). The DNA is size-fractionated on a CHEF gel apparatus and the YAC band is cut out of the low melting point agarose gel. The gel fragment is equilibrated with polyamines and then melted and treated with agarase to digest the agarose. The polyamine-coated DNA is then injected into the male pronucleus of fertilized mouse embryos which are surgically introduced into the uterus of a pseudopregnant female as described above. The transgenic nature of the newborns is analyzed by a slot-blot of DNA isolated from tails and the production of human heavy chain is analyzed by obtaining a small amount of serum and testing it for the presence of Ig chains with rabbit anti-human antibodies.

As an alternative to microinjection, YAC DNA is transferred into murine ES cells by ES cell: yeast protoplast fusion (Traver *et al.*, 1989 *Proc. Natl. Acad. Sci. USA*, 86: 5898-5902; Pachnis *et al.*, 1990, *ibid* 87: 5109-5113). First, the neomycin-resistance gene from pMC1Neo and a yeast selectable marker are inserted into nonessential YAC vector sequences in a plasmid. This construct is used to transform a yeast strain containing the IgH YAC, and pMC1Neo is integrated into vector sequences of the IgH YAC by homologous recombination. The modified YAC is then transferred into an ES cell by protoplast fusion (Traver *et al.*, 1989; Pachnis *et al.*, 1990), and resulting G418-resistant ES cells which contain the intact human IgH sequences are used to generate chimeric mice.

Production of human Ig by chimeric mice Construction of human heavy chain replacement vector.

The replacing human sequences include the SpeI 100 kbp fragment of genomic DNA which encompasses the human VH6-D-J-Cμ-Cδ heavy chain region isolated from a human-YAC library as described before. The flanking mouse heavy chain sequences, which drive the homologous recombination replacement event, contain a 10 kbp BamHI fragment of the mouse Cε-Cα heavy chain and a 5' J558 fragment comprising the 5' half of the J558 fragment of the mouse heavy chain variable region, at the 3' and 5' ends of the human sequences, respectively (Chart 4). These mouse sequences are isolated from a mouse embryo genomic library using the probes described in Tucker *et al.*, *PNAS USA*, 78: 7684-7688, 1981, and Blankenstein and Krawinkel (1987, *supra*), respectively. The 1150 bp XhoI to BamHI fragment, containing a neomycin-resistance gene driven by the Herpes simplex virus thymidine kinase gene (HSV-tk) promoter and a polyoma enhancer is isolated from pMC1Neo (Koller and Smithies, 1989, *supra*). A synthetic adaptor is added onto this fragment to convert the XhoI end into a BamHI end and the resulting fragment is joined to the BamHI mouse Cε-Cα in a plasmid.


From the YAC clone containing the human heavy chain locus, DNA sequences from each end of the insert are recovered either by inverse PCR (Silverman *et al.*, *PNAS*, 86: 7485-7489, 1989), or by plasmid rescue in *E. coli* (Burke *et al.*, 1987; Garza *et al.*, *Science*, 246: 641-646, 1989; Traver *et al.*, 1989) (see Chart 4). The isolated human sequence from the 5'V6 end of the YAC is ligated to the mouse J558 sequence in a plasmid and likewise, the human sequence derived from the 3'Cδ end of the YAC is ligated to the Neo gene in the plasmid containing Neo and mouse Cε-Cα described above. The human V6-mouse J558 segment is now subcloned into a half-YAC cloning vector that includes

EP 0 463 151 B1


a yeast selectable marker (HIS3) not present in the original IgH YAC, a centromere (CEN) and a single telomere (TEL). The human C δ - Neo - mouse C ϵ - C α is likewise subcloned into a separate half-YAC vector with a different yeast selectable marker (LEU2) and a single TEL. The half-YAC vector containing the human V6 DNA is linearized and used to transform a yeast strain that is deleted for the chromosomal HIS3 and LEU2 loci and which carries the IgH YAC. Selection for histidine-prototrophy gives rise to

Chart 4


(A) Human heavy chain locus



(B) Mouse heavy chain locus



(C) Human heavy chain replacement YAC vector



yeast colonies that have undergone homologous recombination between the human V6 DNA sequences and contain a

EP 0 463 151 B1

recombinant YAC. The half-YAC vector containing the human C δ DNA is then linearized and used to transform the yeast strain generated in the previous step. Selection for leucine-prototrophy results in a yeast strain containing the complete IgH replacement YAC (see Chart 4). This YAC is isolated and introduced into ES cells by microinjection as described previously for embryos.

In accordance with the above procedures, an antigenic or chimeric non-primate host, particularly a mouse host, may be produced which can be immunized to produce human antibodies or analogs specific for an immunogen. In this manner, the problems associated with obtaining human monoclonal antibodies are avoided, since mice can be immunized with immunogens which could not be used with a human host. Furthermore, one can provide for booster injections and adjuvants which would not be permitted with a human host. The resulting B-cells may then be used for immortalization for the continuous production of the desired antibody. The immortalized cells may be used for isolation of the genes encoding the immunoglobulin or analog and be subjected to mutation by in-vitro mutagenesis or other mutagenizing technique to modify the properties of the antibodies. These mutagenized genes may then be returned to the immortalized cells for homologous recombination to provide for a continuous mammalian cellular source of the desired antibodies. The subject invention provides for a convenient source of human antibodies, where the human antibodies are produced in analogous manner to the production of antibodies in a human host. The mouse cells conveniently provide for the activation and rearrangement of human DNA in mouse cells for production of human antibodies.

Claims

1. A transgenic non-primate mammal comprising a modified genome wherein said modification comprises a lesion in the J region of at least one copy of the immunoglobulin heavy chain locus wherein said lesion results in the inability of said copy of the locus to rearrange or to produce a functional message encoding an immunoglobulin heavy chain subunit.
2. The mammal of claim 1 wherein said modification further comprises a lesion in at least one copy of an immunoglobulin light chain locus said lesion resulting in the inability of said locus to rearrange or to produce a functional message encoding said light chain subunit.
3. The mammal of claim 1 or 2 wherein said modification comprises lesions in 2 copies of the immunoglobulin heavy chain locus and/or lesions in 2 copies of said immunoglobulin light chain locus.
4. The mammal of any of the preceding claims wherein said modification further comprises inclusion in said genome of an immunoglobulin locus encoding a xenogeneic light chain or heavy chain or both.
5. A transgenic non-primate animal as claimed in any of the preceding claims wherein said non-primate mammal is murine.
6. A transgenic non-primate mammal as claimed in any of the preceding claims wherein the xenogeneic immunoglobulin is human.
7. The transgenic non-primate mammal of any of claims 4-6 wherein the xenogeneic Ig comprises a variable region joined by a peptide bond to a peptide other than solely the Ig constant region.
8. An embryonic stem (ES) cell of a non-primate mammal comprising a modified genome wherein said modification comprises a lesion in at least one copy of the J region of the immunoglobulin heavy chain locus wherein said lesion results in the inability of said copy of the locus to rearrange or to produce a functional message encoding an immunoglobulin heavy chain subunit; and
which optionally further contains
 - a) a lesion in at least one copy of an immunoglobulin light chain locus said lesion resulting in the inability of said locus to rearrange or to produce a functional message encoding said light chain subunit; and/or
 - b) inclusion in the genome of said ES cells of an immunoglobulin locus encoding a xenogeneic light chain or heavy chain or both.
9. The use of the ES cell of claim 8 for the production of a transgenic non-primate mammal.

EP 0 463 151 B1

10. A method for producing xenogeneic antibodies to an antigen which method comprises immunizing the transgenic non-primate mammal of claim 4 with an antigen so as to effect secretion of antibodies by at least some of the B cells of the mammal into the bloodstream; and
- 5 (a) recovering the antibodies from the bloodstream of the animal; or
(b) conducting a process which comprises:
- recovering B cells from the animal;
 - immortalizing the B cells;

10 - screening the immortalized B cells for those immortalized B cells that secrete the antibodies; and

 - recovering the antibodies; or
- (c) performing both process (a) and process (b).
- 15 11. The method of claim 10 wherein the xenogeneic antibodies are human.
12. Immortalized B cells that secrete antibodies which are immunoreactive with a specific antigen wherein the immortalized B cells are derived from a transgenic non-primate mammal as claimed in claim 4 which has been administered said antigen.
- 20 13. A method to produce antibodies immunoreactive with a desired antigen which method comprises culturing the immortalized B cells of claim 12 under conditions wherein said antibodies are secreted; and
- recovering the antibodies from the culture.
- 25 14. The method of claim 13 wherein said antibodies comprise a variable region joined by a peptide bond to a peptide other than solely the Ig constant region.
- 30 15. A method for the production of a transgenic non-primate mammal comprising a modified genome said method comprising creating a lesion in the J region of at least one copy of the immunoglobulin heavy chain locus wherein said lesion results in the inability of said copy of the locus to rearrange or to produce a functional message encoding an immunoglobulin heavy chain subunit.
- 35 16. A method according to claim 15 wherein said method further comprises creating a lesion in at least one copy of an immunoglobulin light chain locus said lesion resulting in the inability of said locus to rearrange or to produce a functional message encoding said light chain subunit.
- 40 17. A method according to claim 15 or 16 wherein said method comprises creating a lesion in 2 copies of the immunoglobulin heavy chain locus and/or lesions in 2 copies of said immunoglobulin light chain locus.
18. A method according to any of claims 15 to 17 wherein said method comprises including in said genome an immunoglobulin locus encoding a xenogeneic light chain or heavy chain or both.
- 45 19. A method according to any one of claims 15 to 18 wherein said non-primate mammal is murine.
20. A method according to any one of claims 15 to 19 wherein the xenogeneic immunoglobulin is human.
- 50 21. A method according to any one of claims 18 to 20 wherein the xenogeneic Ig comprises a variable region joined by a peptide bond to a peptide other than solely the Ig constant region.
- 55 22. A method for the production of an embryonic stem (ES) cell of a non-primate mammal comprising a modified genome, said method comprising creating a lesion in at least one copy of the J-region of the immunoglobulin heavy chain locus wherein said lesion results in the inability of said copy of the locus to rearrange or to produce a functional message encoding an immunoglobulin heavy chain subunit; and
- which optionally further comprises
- a) creating a lesion in at least one copy of an immunoglobulin light chain locus said lesion resulting in the inability of said locus to rearrange or to produce a functional message encoding said light chain subunit; and/or

EP 0 463 151 B1

b) including in the genome of said ES cells an immunoglobulin locus encoding a xenogeneic light chain or heavy chain or both,

23. A method for the production of immortalized B cells that secrete antibodies which are immunoreactive with a specific antigen said method comprising deriving the immortalized B cells from a transgenic non-primate mammal as claimed in claim 4 or 18 which has been administered said antigen.

Patentansprüche

1. Transgenes Nichtprimaten-Säugetier, enthaltend ein modifiziertes Genom, wobei die Modifikation eine Läsion in der J-Region von mindestens einer Kopie des Immunoglobulin-schwere Ketten-Locus umfaßt, wobei diese Läsion zur Unfähigkeit dieser Kopie des Locus zur Umlagerung oder zur Erzeugung einer funktionellen Botschaft, die für eine Immunoglobulin-schwere Ketten-Untereinheit kodiert, führt.

2. Säugetier nach Anspruch 1, wobei die Modifikation ferner eine Läsion in mindestens einer Kopie eines Immunoglobulin-leichte Ketten-Locus umfaßt, wobei die Läsion zur Unfähigkeit des Locus zur Umlagerung oder zur Erzeugung einer funktionellen Botschaft, die für die leichte Ketten-Untereinheit kodiert, führt.

3. Säugetier nach Anspruch 1 oder 2, wobei die Modifikation Läsionen in zwei Kopien des Immunoglobulin-schwere Ketten-Locus und/oder Läsionen in zwei Kopien des Immunoglobulin-leichte Ketten-Locus umfaßt.

4. Säugetier nach einem der vorstehenden Ansprüche, wobei die Modifikation ferner den Einbau eines Immunoglobulin-Locus, der für eine xenogene leichte Kette oder schwere Kette oder beides kodiert, in das Genom umfaßt.

5. Transgenes Nichtprimaten-Tier nach einem der vorstehenden Ansprüche, wobei es sich beim Nichtprimaten-Säugetier um eine Maus handelt.

6. Transgenes Nichtprimaten-Säugetier nach einem der vorstehenden Ansprüche, wobei es sich beim xenogenen Immunoglobulin um ein humanes Immunoglobulin handelt.

7. Transgenes Nichtprimaten-Säugetier nach einem der Ansprüche 4 bis 6, wobei das xenogene Ig eine variable Region umfaßt, die durch eine Peptidbindung mit einem Peptid verbunden ist, das von der bloßen konstanten Ig-Region abweicht.

8. Embryonale Stammzelle (ES) eines Nichtprimaten-Säugetiers, enthaltend ein modifiziertes Genom, wobei die Modifikation eine Läsion in mindestens einer Kopie der J-Region des Immunoglobulin-schwere Ketten-Locus umfaßt, wobei die Läsion zur Unfähigkeit der Kopie des Locus zur Umlagerung oder zur Erzeugung einer funktionellen Botschaft, die für eine Immunoglobulin-schwere Ketten-Untereinheit kodiert, führt; und die ggf. ferner folgendes enthält:

a) eine Läsion in mindestens einer Kopie eines Immunoglobulin-leichte Ketten-Locus, wobei die Läsion zur Unfähigkeit des Locus zur Umlagerung oder zur Erzeugung einer funktionellen Botschaft, die für die leichte Ketten-Untereinheit kodiert, führt; und/oder

b) Einbau in das Genom der ES-Zellen eines Immunoglobulin-Locus, der für eine xenogene leichte Kette oder schwere Kette oder beides kodiert.

9. Verwendung der ES-Zelle nach Anspruch 8 zur Erzeugung eines transgenen Nichtprimaten-Säugetiers.

10. Verfahren zur Erzeugung von xenogenen Antikörpern gegen ein Antigen, wobei das Verfahren folgendes umfaßt: Immunisieren des transgenen Nichtprimaten-Säugetiers nach Anspruch 4 mit einem Antigen, um eine Sekretion von Antikörpern durch mindestens einige der B-Zellen des Säugetiers in den Blutstrom herbeizuführen; und

(a) Gewinnen der Antikörper aus dem Blutstrom des Tiers; oder
(b) Durchführen eines Verfahrens, das folgendes umfaßt:

- Gewinnen von B-Zellen aus dem Tier;
- Immortalisieren der B-Zellen;

EP 0 463 151 B1

- Screening der immortalisierten B-Zellen auf solche immortalisierte B-Zellen, die die Antikörper sekretieren; und
- Gewinnen der Antikörper; oder

5 (c) Durchführen beider Verfahren (a) und (b).

11. Verfahren nach Anspruch 10, wobei die xenogenen Antikörper human sind.

10 12. Immortalisierte B-Zellen, die Antikörper sekretieren, die mit einem spezifischen Antigen immunoreaktiv sind, wobei die immortalisierten B-Zellen von einem transgenen Nichtprimaten-Säugetier nach Anspruch 4, dem das Antigen verabreicht worden ist, abgeleitet sind.

13. Verfahren zur Erzeugung von Antikörpern, die mit einem gewünschten Antigen immunoreaktiv sind, wobei das Verfahren folgendes umfaßt: Züchten der immortalisierten B-Zellen nach Anspruch 12 unter Bedingungen, bei denen die Antikörper sekretiert werden; und

- Gewinnen der Antikörper aus der Kultur.

20 14. Verfahren nach Anspruch 13, wobei die Antikörper eine variable Region umfassen, die durch eine Peptidbindung mit einem Peptid verbunden ist, das von der bloßen konstanten Ig-Region abweicht.

25 15. Verfahren zur Erzeugung eines transgenen Nichtprimaten-Säugetiers, das ein modifiziertes Genom enthält, wobei das Verfahren folgendes umfaßt: Erzeugen einer Läsion in der J-Region von mindestens einer Kopie des Immunoglobulin-schwere Ketten-Locus, wobei die Läsion zur Unfähigkeit der Kopie des Locus zur Umlagerung oder zur Erzeugung einer funktionellen Botschaft, die für eine Immunoglobulin-schwere Ketten-Untereinheit kodiert, führt.

30 16. Verfahren nach Anspruch 15, wobei das Verfahren ferner folgendes umfaßt: Erzeugung einer Läsion in mindestens einer Kopie eines Immunoglobulin-leichte Ketten-Locus, wobei die Läsion zur Unfähigkeit des Locus zur Umlagerung oder zur Erzeugung einer funktionellen Botschaft, die für die leichte Ketten-Untereinheit kodiert, führt.

35 17. Verfahren nach Anspruch 15 oder 16, wobei das Verfahren die Erzeugung einer Läsion in zwei Kopien des Immunoglobulin-schwere Ketten-Locus und/oder von Läsionen in zwei Kopien des Immunoglobulin-leichte Ketten-Locus umfaßt.

18. Verfahren nach einem der Ansprüche 15 bis 17, wobei das Verfahren den Einbau eines Immunoglobulin-Locus, der für eine xenogene leichte Kette oder eine schwere Kette oder beides kodiert, in das Genom umfaßt.

40 19. Verfahren nach einem der Ansprüche 15 bis 18, wobei es sich beim Nichtprimaten-Säugetier um eine Maus handelt.

20. Verfahren nach einem der Ansprüche 15 bis 19, wobei das xenogene Immunoglobulin human ist.

45 21. Verfahren nach einem der Ansprüche 18 bis 20, wobei das xenogene Ig eine variable Region umfaßt, die durch eine Peptidbindung an ein Peptid gebunden ist, das von der bloßen konstanten Ig-Region abweicht.

50 22. Verfahren zur Erzeugung einer embryonalen Stammzelle (ES) eines Nichtprimaten-Säugetiers, enthaltend ein modifiziertes Genom, wobei das Verfahren folgendes umfaßt: Erzeugen einer Läsion in mindestens einer Kopie der J-Region des Immunoglobulin-schwere Ketten-Locus, wobei die Läsion zur Unfähigkeit der Kopie des Locus zur Umlagerung oder zur Erzeugung einer funktionellen Botschaft, die für eine Immunoglobulin-schwere Ketten-Untereinheit kodiert, führt; und wobei das Verfahren ggf. ferner folgendes umfaßt:

- (a) Erzeugen einer Läsion in mindestens einer Kopie eines Immunoglobulin-leichte Ketten-Locus, wobei die Läsion zur Unfähigkeit des Locus zur Umlagerung oder zur Erzeugung einer funktionellen Botschaft, die für die leichte Ketten-Untereinheit kodiert, führt; und/oder
- (b) Einbau in das Genom der ES-Zellen eines Immunoglobulin-Locus, der für eine xenogene leichte Kette oder schwere Kette oder beides kodiert.

EP 0 463 151 B1

23. Verfahren zur Erzeugung von immortalisierten B-Zellen, die Antikörper sekretieren, die mit einem spezifischen Antigen immunoreaktiv sind, wobei das Verfahren die Ableitung der immortalisierten B-Zellen aus einem transgenen Nichtprimaten-Säugetier nach Anspruch 4 oder 18, dem das Antigen verabreicht worden ist, umfaßt.

5

Revendications

1. Mammifère non primate transgénique comprenant un génome modifié dans lequel cette modification comprend une lésion dans la région J d'au moins une copie de l'emplacement de la chaîne lourde de l'immunoglobuline dans lequel cette lésion conduit à l'incapacité de cette copie de l'emplacement de se réarranger ou de produire un message fonctionnel codant pour une sous-unité de la chaîne lourde de l'immunoglobuline.
2. Mammifère selon la revendication 1, dans lequel cette modification comprend en outre une lésion dans au moins une copie de l'emplacement d'une chaîne légère d'immunoglobuline, cette lésion conduisant à l'incapacité de cet emplacement de se réarranger ou de produire un message fonctionnel codant pour cette sous-unité de la chaîne légère.
3. Mammifère selon la revendication 1 ou 2, dans lequel cette modification comprend des lésions dans deux copies de l'emplacement de la chaîne lourde de l'immunoglobuline et/ou des lésions dans deux copies de cet emplacement de la chaîne légère de l'immunoglobuline.
4. Mammifère selon l'une quelconque des revendications précédentes, dans lequel cette modification comprend en outre l'inclusion dans ce génome d'un emplacement de l'immunoglobuline codant pour une chaîne légère ou une chaîne lourde xénogéniques ou les deux.
5. Animal non primate transgénique selon l'une quelconque des revendications précédentes, dans lequel ce mammifère non primate est un murin.
6. Mammifère non primate transgénique selon l'une quelconque des revendications précédentes, dans lequel l'immunoglobuline xénogénique est humaine.
7. Mammifère non primate transgénique selon l'une quelconque des revendications 4 à 6, dans lequel l'Ig xénogénique comprend une région variable unie par une liaison peptidique à un peptide autre que la seule région constante de l'Ig.
8. Cellule souche embryonnaire (ES) d'un mammifère non primate comprenant un génome modifié dans lequel cette modification comprend une lésion dans au moins une copie de la région J de l'emplacement de la chaîne lourde de l'immunoglobuline, dans lequel cette lésion entraîne l'incapacité de cette copie de l'emplacement de se réarranger ou de produire un message fonctionnel codant pour une sous-unité de la chaîne lourde de l'immunoglobuline; et
qui contient en outre facultativement
 - a) une lésion dans au moins une copie d'un emplacement de la chaîne légère de l'immunoglobuline, cette lésion entraînant l'incapacité de cet emplacement de se réarranger ou de produire un message fonctionnel codant pour cette sous-unité de chaîne légère; et/ou
 - b) l'inclusion dans le génome de ces cellules ES d'un emplacement de l'immunoglobuline codant pour une chaîne légère ou une chaîne lourde xénogéniques ou les deux.
9. Utilisation de la cellule ES selon la revendication 8 pour la production d'un mammifère non primate transgénique.
10. procédé de production d'anticorps xénogéniques contre un antigène, lequel procédé comprend le fait d'immuniser le mammifère non primate transgénique selon la revendication 4 avec un antigène de manière à provoquer une sécrétion d'anticorps par au moins certaines des cellules B du mammifère dans le courant sanguin; et
 - (a) le fait de récupérer les anticorps dans le courant sanguin de l'animal; ou
 - (b) le fait de conduire un processus qui comprend :
 - le fait de récupérer les cellules B de l'animal;

EP 0 463 151 B1

- le fait de rendre immortelles les cellules B;
- le fait de sélectionner parmi les cellules immortalisées B celles qui sécrètent les anticorps; et
- le fait de récupérer les anticorps; ou

5 (c) le fait d'effectuer les deux processus (a) et (b).

11. Procédé selon la revendication 10, dans lequel les anticorps xénogéniques sont des anticorps humains.

10 12. Cellules B immortalisées qui sécrètent des anticorps qui sont immunoréactifs avec un antigène spécifique, les cellules B immortalisées étant obtenues à partir d'un mammifère non primate transgénique selon la revendication 4 auquel on a administré cet antigène.

15 13. Procédé de production d'anticorps immunoréactifs avec un antigène désiré, lequel procédé comprend le fait de cultiver les cellules B immortalisées selon la revendication 12 dans les conditions dans lesquelles ces anticorps sont sécrétés; et

- le fait de récupérer les anticorps dans la culture.

20 14. Procédé selon la revendication 13, dans lequel ces anticorps comprennent une région variable unie par une liaison peptidique à un peptide autre que la seule région constante de l'Ig.

25 15. Procédé pour la production d'un mammifère non primate transgénique comprenant un génome modifié, ce procédé comprenant le fait de créer une lésion dans la région J d'au moins une copie de l'emplacement de chaîne lourde de l'immunoglobuline, dans lequel cette lésion conduit à l'incapacité de cette copie de l'emplacement de se réarranger ou de produire un message fonctionnel codant pour une sous-unité de la chaîne lourde de l'immunoglobuline.

30 16. Procédé selon la revendication 15, dans lequel ce procédé comprend en outre le fait de créer une lésion dans au moins une copie d'un emplacement de la chaîne légère de l'immunoglobuline, cette lésion conduisant à l'incapacité de cet emplacement de se réarranger ou de produire un message fonctionnel codant pour cette sous-unité de la chaîne légère.

35 17. Procédé selon les revendications 15 ou 16, comprenant le fait de créer une lésion dans deux copies de l'emplacement de la chaîne lourde de l'immunoglobuline et/ou des lésions dans deux copies de cet emplacement de la chaîne légère de l'immunoglobuline.

40 18. Procédé selon l'une quelconque des revendications 15 à 17, comprenant le fait d'incorporer à ce génome un emplacement de l'immunoglobuline codant pour une chaîne légère ou une chaîne lourde xénogéniques ou les deux.

45 19. Procédé selon l'une quelconque des revendications 15 à 18, dans lequel ce mammifère non primate est un murin.

20. Procédé selon l'une quelconque des revendications 15 à 19, dans lequel l'immunoglobuline xénogénique est humaine.

45 21. Procédé selon l'une quelconque des revendications 18 à 20, dans lequel l'Ig xénogénique comprend une région variable unie par une liaison peptidique à un peptide autre que la seule région constante de l'Ig.

50 22. Procédé pour la production d'une cellule souche embryonnaire (ES) d'un mammifère non primate comprenant un génome modifié, ce procédé comprenant le fait de créer une lésion dans au moins une copie de la région J de l'emplacement de la chaîne lourde de l'immunoglobuline, dans lequel cette lésion conduit à l'incapacité de cette copie de l'emplacement de se réarranger ou de produire un message fonctionnel codant pour une sous-unité de la chaîne lourde de l'immunoglobuline; et
qui comprend en outre facultativement

55 a) le fait de créer une lésion dans au moins une copie d'un emplacement de la chaîne légère de l'immunoglobuline, cette lésion entraînant l'incapacité de cet emplacement de se réarranger ou de produire un message fonctionnel codant pour cette sous-unité de chaîne légère; et/ou

EP 0 463 151 B1

b) le fait d'incorporer au génome de ces cellules ES un emplacement de l'immunoglobuline codant pour une chaîne légère ou pour une chaîne lourde xénogéniques ou les deux.

- 5 23. Procédé pour la production de cellules B immortalisées qui sécrètent des anticorps, lesquels sont immunoréactifs avec un antigène spécifique, ce procédé comprenant le fait d'obtenir les cellules B immortalisées à partir d'un mammitère non primate transgénique selon la revendication 4 ou la revendication 18 auquel on a administré cet antigène.

10

15

20

25

30

35

40

45

50

55